Identification and characterization of the cDNA encoding rat neuropeptide Y revealed the nucleotide sequence coding for a 98-amino acid precursor. The deduced amino acid sequence for rat neuropeptide Y is identical to the human peptide and is highly homologous to avian pancreatic polypeptide. The tertiary structure of avian pancreatic polypeptide has been previously derived from crystallographic data by Blundell and coworkers. The homology between neuropeptide Y and avian pancreatic polypeptide preserves all of the residues essential for the maintenance of the tertiary structure. Thus, it has been possible to compute a three-dimensional model of the mammalian neuropeptide, neuropeptide Y, based on the known structure of the avian homologue. This model suggests that neuropeptide preserves a compact tertiary structure characterized by extensive hydrophobic interactions between an N-terminal polyproline-II-like helix and a C-terminal a-helix. The model has been used to identify amino acids residing in key positions within this structure and, thereby, to direct future analysis of neuropeptide Y structure-function relationships.
Neurons produce a variety of peptides that are secreted from axons and dendrites and are collectively known as neuropeptides. These peptides arise from larger precursors that are processed enzymatically to yield the mature neuropeptides (1) . Neuropeptides are believed to serve as neurotransmitters and neuromodulators (2) by their interaction with specific cell membrane receptors after secretion and have been implicated in the control of behavior and autonomic and motor functions.
Understanding the synthesis and secretion of neuropeptides and their mechanism of action requires detailed knowledge of the molecular structure of neuropeptides and neuropeptide precursors. To gain such knowledge, we have combined the methods of molecular cloning of cDNAs complementary to specific mRNAs with computer-aided molecular modeling to deduce both the primary and tertiary structures of the mammalian neuropeptide "neuropeptide Y" (NPY). This neuropeptide was originally identified by chemical means and subsequently purified from porcine brain (3, 4) . NPY is widely distributed throughout the mammalian central (5, 6) and peripheral nervous systems (7, 8) . Central administration has implicated NPY in the control of feeding (9, 10) and in secretion of gonadotrophin-releasing hormone secretion (11) . Peripheral administration of NPY induces vasoconstriction in many vascular beds (12) (13) (14) and potentiates catecholamine-induced vascular smooth muscle contraction in vitro (15) . NPY may play a role in degenerative diseases such as Alzheimer's disease (16) . The structure of the precursor of human NPY was recently determined by molecular cloning methods (17) .
NPY is a member of a larger family that includes the pancreatic polypeptide (18) and peptide YY (19) (Table 1 ). In particular, NPY is highly homologous in amino acid sequence to avian pancreatic polypeptide (APP), these two having 19 of the total 36 amino acids in common (4) . The three-dimensional structure of APP was recently solved by x-ray crystallography at high resolution (20) .
We deduced the amino acid sequence of rat NPY from the nucleotide sequence of the mRNA that encodes the rat NPY precursor. We then took advantage of the extensive homology between NPY and APP to construct an approximate three-dimensional model of rat NPY using the conformational search program CONGEN (21) .
MATERIALS AND METHODS
Identification, Subcloning, and Nucleotide Sequence Analysis of a cDNA Encoding Rat NPY mRNA. A cDNA library constructed in bacteriophage Xgtll from rat hypothalamic mRNA template (R. H. Goodman, Tufts University School of Medicine, Boston) was screened by the plaque-hybridization method of Benton and Davis (22) .
A double-stranded oligodeoxynucleotide of 60 base pairs corresponding to nucleotides 228-287 of a cDNA encoding human NPY (17) was used as hybridization probe. 32P-labeled double-stranded DNA was prepared enzymatically with Escherichia coli DNA polymerase I (Klenow fragment) from two oligonucleotides (33 and 34 nucleotides) synthesized by the phosphoramidite method (23) so that the 3' end of the shorter oligonucleotide was complementary to 7 bases at the 3' end of the longer one.
Plaque hybridization with heat-denatured 32P-labeled double-stranded DNA was carried out in 1 M NaCl at 55°C. Phages from specifically hybridizing plaques were purified, and DNA was extracted from pure phages and digested with restriction endonuclease EcoRI to release cloned cDNA from the unique cloning site (EcoRI) of the vector. The cDNA insert was then ligated into the EcoRI site of the vector pGem3 (Promega Biotec, Madison, WI), transfected into E. coli c600, and prepared in bulk for mapping of restriction endonuclease sites. DNA at the sites indicated in Fig. 1 was labeled with 32P at the 5' or 3' ends by using polynucleotide kinase and the Klenow fragment of E. coli DNA polymerase I, and the DNA was digested with a second enzyme or the strands were separated to prepare fragments labeled on a single strand. The nucleotide sequences of the resulting DNA fragments were then determined by the chemical method of Abbreviations: NPY, neuropeptide Y; APP, avian pancreatic polypeptide.
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Maxam and Gilbert (24) according to the strategy outlined in Fig. 1 . Computational Methods. Crystallographic coordinates of APP (20) were obtained from the Brookhaven Protein Data Bank (25) . Structural manipulations and potential energy evaluations were performed with the program CHARMM version 16 (26) in explicit hydrogen atom representation. That is, the polar hydrogen atoms were explicitly constructed by the program, while nonpolar hydrogens were combined with the carbon atoms into "extended" atoms. Conformational space of side chains was searched by using the procedure CONGEN (21) with a 30°grid applied to all torsional degrees of freedom with the exception of lysine and arginine side chains, where the torsional angles were chosen according to the minimum potential energy criterion. The constrained energy minimization protocol was that of Bruccoleri and Karplus (27) . Solvent accessibility was computed by using the Lee and Richards algorithm (28) . Electrostatic energy of both the APP and NPY structures was computed from the Coulomb formula with the dielectric constant equal to 50 and was evaluated to infinity (29) . Color-coded molecular graphics were produced with the program FRODO as implemented on Evans and Sutherland picture systems 340 (30) and modified by M. Handschumacher (Massachusetts General Hospital, Boston).
RESULTS
Characterization and Nucleotide Sequence Analysis of NPY cDNAs. At least 8 independent recombinant bacteriophages of 100,000 screened hybridized specifically to the synthetic hybridization probe. Five of these were purified, and DNA was prepared and analyzed by restriction enzyme digestion and Southern blot hybridization. These analyses revealed that in 3 phages the EcoRI cloning sites had become nonfunctional. Therefore, the rat DNA was released from the remaining 2 phages with EcoRI and cloned into the unique EcoRI site of the cloning vector pGem3. These subclones were designated NPY-5 and NPY-7. Complete maps of restriction endonuclease sites of the rat DNA inserts of NPY-5/7 were established by polyacrylamide gel electrophoresis of digests of NPY-5/7 DNA and by blot hybridization with the synthetic oligonucleotides constructed according to the rat NPY mRNA sequence. The restriction site map of the NPY-5 insert is shown in Fig. 1 and was identical for NPY-7.
The nucleotide sequence of the NPY-5 insert was determined according to the strategy outlined in Fig. 1 complete nucleotide sequences of both strands agreed with one another and are shown in Fig. 2 . The nucleotide sequence of the NPY-5 insert revealed a high degree of homology with the reported human NPY mRNA sequence. Therefore, nucleotides 1-68 of NPY-5 must represent the 5' untranslated region of rat NPY mRNA; nucleotides 69-365, the translated region; and nucleotides 366-539, the 3' untranslated region. The presence of 20 adenosine residues at the 3' end preceded by a typical 
Cys Lou Gly Ile Lou Ala Glu Gly Tyr Pro Ser Lys Pro Asp TGT TTG GGC ATT CTG GCT GAG CGG TAC CCC TCC AAG CCG GAC
Asn Pro Gly Glu Asp Ala Pro Ala Glu
Tyr Ser Ala Leu Arg His Tyr Ile Asn Leu Ile Thr Arg Gln AATAAA polyadenylylation signal suggests that NPY-5 contains a complete 3' untranslated region. However, NPY-5 may be incomplete at the 5' end. The number of missing nucleotides must be small inasmuch as blot-hybridization analysis indicates that rat and human NPY mRNA are similar in size, as are NPY-5 and the reported human NPY cDNA (Fig. 3) . Moreover, preliminary analysis of the cloned rat NPY gene also suggests that NPY-5 contains a nearly complete 5' untranslated region. Thus, NPY-5 appears to carry a complete representation of rat NPY mRNA.
Rat NPY mRNA encodes a 98-amino acid precursor of NPY with a signal sequence of 29 amino acids, followed by NPY (36 amino acids), 3 amino acids (glycine, lysine, and arginine) necessary for posttranslational processing, and the C-terminal flanking peptide of 30 (20) . The peptide in the crystals has a globular structure with residues 2-8 assuming a left-handed polyproline-II-like helix that is closely packed through hydrophobic interactions against an a-helix formed by residues 14-32. Unlike pancreatic glucagon, which appears to have a flexible structure in dilute aqueous solutions, this secondary structure seen in the APP crystals is known to be maintained in solution (20) . The initial potential energy of the crystallographic structure, as evaluated by the program CHARMM, was positive, but upon energy minimization it converged to the value of -1053 kJ/mol (-252 In constructing the NPY model, coordinates of the backbone atoms and the side chains conserved between the two sequences were copied directly into the model. The missing side chains were then constructed by using the conformational search procedure CONGEN, which finds positions of potential energy minima in the side-chain torsional space. The CONGEN-constructed model was then subjected to the same energy-minimization protocol as the crystallographic APP structure and, upon root-mean-square adjustments of atomic positions of about 30 pm (0.3 A), a structure was obtained with potential energy -1041 kJ/mol (-249 kcal/ mol), comparable to that of the APP (Fig. 4) .
It has been shown that the potential energy in vacuo as used, for example, in the program CHARMM distinguishes poorly between correctly and incorrectly modeled structures, whereas the size and nature of molecular surfaces and solvent-modified electrostatic energy values have much greater diagnostic value (32) . Accordingly, the solventaccessible surfaces and electrostatic energies were computed and compared for the two structures, the APP and NPY model ( Table 2 ). It can be seen that the surface characteristics of the crystallographic APP structure and the NPY model are essentially the same-i.e., 32.9-nm2 total molecular surface of APP, 52% of which was hydrophobic, and 32.2-nm2 molecular surface of the NPY model, 56% of which was hydrophobic atoms. In particular, the nature of the contact surface between the two helical secondary structures is very similar in both peptides, and the NPY model actually seems to be stabilized by somewhat larger intramolecular contacts (10.2-nm2 contact surface compared to 9.4-nm2 contact surface of the APP). Likewise, the electrostatic energies of the two structures evaluated to infinity with the dielectric constant of 50 were comparable, and the model appeared to be stabilized by significantly larger electrostatic forces than in the parent crystal structure (-16.3 kJ/mol or -3.9 kcal/mol, compared to -8.3 kJ/mol or -2.0 kcal/mol in the APP).
DISCUSSION
We have cloned and sequenced a cDNA that represents NPY mRNA. Analysis of the coding region revealed that rat and human NPY are identical. Moreover, the amino acid sequences of rat, human, and porcine NPY are highly homologous to APP (Table 1) . This remarkable homology preserves all of the residues important for the APP secondary structure and has allowed us to construct a three-dimensional structure model of mammalian NPY based on the known crystallographic structure of the avian homologue, APP. This model suggests (i) that, consistent with present knowledge of NPY pharmacology and receptor binding, NPY probably possesses a compact tertiary structure (Fig. 5) ; and (ii) that several amino acids residing in key positions should be the focus of future analyses of NPY structure-function relationships. By using the deduced amino acid sequence of rat NPY, a three-dimensional model was computer-generated from the crystal structure of the homologous APP. The method of homologous modeling has been criticized (32) and has been shown to lead to incorrect results, at least in some cases (33, 34) . However, the small size of the two peptides APP and NPY considered here (36 amino acids), the refined modeling protocol used here (an exhaustive search of side-chain conformational space), and a high degree of homology between APP and NPY that conserves all of the unique traits of the APP sequence strongly suggest that our NPY model captures correctly the most essential features of its tertiary structure. The residues most important for the APP tertiary structure are those mediating helix-helix contacts-namely, the proline residues 2, 5, and 8, and 13 of the polyproline helix and the a-helicAl residues leucine-17, phenylalanine-20, leucine-24, tyrosine-27, and valine-30. All of these residues are either conserved in the NPY molecule or replaced by chem- remarkable features of the NPY model that emerges from our study is its extensive and compact tertiary structure, as stabilized by the intramolecular contacts between a polyproline helix and the a-helix. These two parts of the molecule are brought together by a tight hairpin fold so that the N and C termini of NPY come to spatial proximity (Fig. 5) .
Certain structural requirements for the biological and pharmacological effects of NPY have been investigated. Deamidation of the C-terminal tyrosine was found to result in complete loss of activity in an in vitro ileal preparation (35) , although this amide group appears to contribute little to the crystal structure of APP (20) and the tertiary structure of the NPY model. Similarly, deletion of the N-terminal tyrosine resulted in marked reduction in vasoconstrictor potency (36) . Interestingly, N-terminal deletion fragments are ineffective inhibitors of NPY receptor binding in parallel with decreased potency (37) . Thus, it appears that both the C-and N-terminal regions of NPY are required for bioactivity and that receptor binding and activation may reside in N and C termini, respectively.
The N-terminal tyrosine could be involved in NPY receptor binding either directly or indirectly. That is, the solventexposed part of this tyrosine side chain may interact directly with NPY receptor residues, or, alternatively, its buried part may stabilize and be crucial for integrity of the NPY structure. Inasmuch as APP has a glycine in position 1 and is a poor competitive inhibitor of NPY binding, we favor the first possibility. The alternative roles of Tyr-1 and the possible contributions of other residues to NPY structure, biologic activity, and receptor binding can now be tested specifically on the basis of our model. For example, it is already known by receptor binding kinetics that the related peptide, PYY, is a good competitive ligand for the NPY receptor. These two peptides possess virtually identical residues to each other in their N-and C-terminal regions, further emphasizing the importance of these regions in receptor binding, as suggested by the model for NPY proposed in this study. The two peptides diverge in amino acid content within the middle regions; thus, substitutions within this area appear to be tolerated without affecting receptor binding. The behavior of these naturally occurring homologues, PYY and APP, in receptor binding studies provides additional information for defining key amino acid residues.
In this model, substitutions of internal residues in the a-helix (positions 20, 24, 27, and 30) with polar residues should destabilize the a-helix/proline-helix interactions, whereas substitutions of external residues (positions 19, 22, and 26) should have no effect on these interactions but rather should alter the solvent-accessible surface and thereby possible receptor interactions at putative sites distant from the N and C termini. For example, does replacement of Tyr-1 with glycine significantly lower receptor binding? On the other hand, the deamidated NPY analogue should bind to the receptor as well as NPY. These and similar modifications in key positions when rationalized by computer-aided analyses of the NPY model should serve both to further test the validity of the modeling approach and to lead to a more detailed understanding of the structure and function of neuropeptides in central and peripheral nervous systems.
